We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients (Preedom)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00768196
First Posted: October 7, 2008
Last Update Posted: December 7, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
The purpose of this study is to asses the EED symptom prevalence in Koran GERD patients with typical reflux symptom and to evaluate quality of life with the scales including Gerd Q.

Condition
Gastroesophageal Reflux Disease

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • The primary variable is the total rate of GERD patients who had EED symptom and effect on their quality of life.

Secondary Outcome Measures:
  • The secondary variable is the comparison of the EED symptom frequency in ERD and NERD patients.

Estimated Enrollment: 2000
Study Start Date: September 2008
Study Completion Date: February 2009
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
general hospital sample
Criteria

Inclusion Criteria:

  • GERD patients who have experienced heartburn or acid regurgitation during past 7 days
  • GERD patients who have already undergone endoscopy before enrolment

Exclusion Criteria:

  • Involvement in the planning and conduct of the programme
  • The person who took the medicine such as PPI or H2RA during the last 7 days
  • Severe systemic disease
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00768196


Locations
Korea, Republic of
Research Site
Cheonan, Chungnam, Korea, Republic of
Research Site
Seoul, Kyungkido, Korea, Republic of
Research Site
Sungnam, Kyungkido, Korea, Republic of
Research Site
Suwon, Kyungkido, Korea, Republic of
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Joon-Woo Bahn AstraZeneca Korea
  More Information

ClinicalTrials.gov Identifier: NCT00768196     History of Changes
Other Study ID Numbers: NIS-GKR-DUM-2008/1
First Submitted: October 1, 2008
First Posted: October 7, 2008
Last Update Posted: December 7, 2010
Last Verified: December 2010

Keywords provided by AstraZeneca:
GERD
Korea
typical symptom
quality of life
Naturalistic
epidemiological

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases